The glucocorticoid receptor modulator relacorilant reverses the immunosuppressive effects of cortisol.
Autor: | Greenstein AE; Corcept Therapeutics, 149 Commonwealth Dr, Menlo Park, CA 94025, USA. Electronic address: agreenstein@corcept.com., Hunt HJ; Corcept Therapeutics, 149 Commonwealth Dr, Menlo Park, CA 94025, USA. Electronic address: hhunt@corcept.com. |
---|---|
Jazyk: | angličtina |
Zdroj: | International immunopharmacology [Int Immunopharmacol] 2023 Jul; Vol. 120, pp. 110312. Date of Electronic Publication: 2023 May 23. |
DOI: | 10.1016/j.intimp.2023.110312 |
Abstrakt: | Cortisol, an endogenous glucocorticoid receptor (GR) agonist, controls a broad transcriptional program that affects T-cell activation, pro-inflammatory cytokine secretion, apoptosis, and immune-cell trafficking. The degree to which endogenous cortisol blunts the anti-tumor immune response checkpoint inhibitors stimulate had not been assessed. We addressed this question using relacorilant, a selective GR modulator (SGRM) that competitively antagonizes the effects of cortisol activity. GR expression in human tumor and immune cells positively correlated with PD-L1 expression and tumor infiltration of Th2 and T Competing Interests: Declaration of Competing Interest AEG and HJH are employees and stockholders of Corcept Therapeutics, the company developing relacorilant. The authors have no additional relevant financial interests. (Copyright © 2023. Published by Elsevier B.V.) |
Databáze: | MEDLINE |
Externí odkaz: |